Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1493304

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1493304

U.S. Regulatory Affairs Market Size, Share & Trends Analysis Report By Services, By Category, By Indication, By Product Stage, By Service Provider, By Company Size, By End-use, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 80 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 3950
Printable PDF (5-User License)
USD 4950
Printable PDF (Enterprise License)
USD 6950

Add to Cart

Description

Table of Contents

List of Tables

U.S. Regulatory Affairs Market Growth & Trends:

The U.S. regulatory affairs market is anticipated to reach USD 7.71 billion by 2030 and is anticipated to expand at a CAGR of 9.0% during the forecast period, according to a new report by Grand View Research, Inc. The regulatory landscape constantly evolves and becomes more complex, with new laws and guidelines being introduced regularly. This complexity drives the demand for regulatory affairs professionals who can navigate these intricate requirements.

As the company expands its operations globally, regulatory compliance becomes more challenging due to varying regulations across different countries. Regulatory affairs professionals help organizations navigate international regulatory frameworks and ensure market access. For instance, as per Reuters update of Jan 2024, many U.S. law corporations are expected to enter into merger agreements in 2024. Stockton & Kilpatrick Townsend recently announced a merger with smaller companies. In addition, Fennemore Craig, a Phoenix-founded medium-sized company, announced its expansion into Seattle in the current year.

Regulatory bodies prioritize patient safety and product quality, leading to stringent regulations that companies must adhere to. Regulatory affairs professionals are vital in ensuring products meet these standards while expediting the approval process. As the healthcare industry expands and competition increases, companies must stay ahead by complying with regulations efficiently. Regulatory affairs expertise becomes a competitive advantage in launching products faster while meeting regulatory requirements.

U.S. Regulatory Affairs Market Report Highlights:

  • Regulatory writing & publishing dominated the services segment with more than 16% share in 2023 owing to increasing outsources of these services by mid- and large size medical device and biopharmaceutical firms.
  • The legal representation segment is expected to grow at the fastest CAGR over the forecast period.
  • The medical devices segment held the largest market share in 2023. This is attributable to the rising outsource activities of medical devices by pharmaceutical firms allowing them to focus on their underlying competencies.
  • Oncology accounted for the largest market revenue share in 2023.This can be attributed to the growing prevalence of cancer cases, encouraging a demand for effective and safe treatment selections.
  • The immunology segment is expected to grow at the fastest CAGR of 10.5% during the forecast period owing to its capability to facilitate the treatment of several neurological, cardiovascular, inflammatory, and oncological diseases.
  • Clinical studies accounted for the largest market revenue share in 2023 owing to the growing incidences of new diseases and the increasing occurrence of chronic illnesses.
  • Outsourced service provider accounted for the largest market revenue share in 2023 and is anticipated to grow at the fastest CAGR over the forecast period.
  • The medium size companies accounted for the largest market revenue share in 2023 owing to the existence of several mid-sized recognized providers, specifically privately held, is anticipated to promote to the segment's growth.
  • The pharmaceutical companies segment dominated the market in 2023 and is anticipated to grow at the fastest CAGR over the forecast period attributing to the expansion in the number of authorized pharmaceutical products.
Show more
Product Code: GVR-4-68040-278-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service
    • 1.2.2. Category
    • 1.2.3. Indication
    • 1.2.4. Product Stage
    • 1.2.5. Service Provider
    • 1.2.6. Company Size
    • 1.2.7. End-use
    • 1.2.8. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service outlook
    • 2.2.2. Category outlook
    • 2.2.3. Indication outlook
    • 2.2.4. Product stage outlook
    • 2.2.5. Service provider outlook
    • 2.2.6. Company size outlook
    • 2.2.7. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Regulatory Affairs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Regulatory Affairs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Regulatory Affairs Market: Service Estimates & Trend Analysis

  • 4.1. Service Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Regulatory Affairs Market by Service Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Regulatory Consulting
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Legal Representation
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Regulatory Writing & Publishing
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.1.1. Writing
      • 4.4.3.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.1.2. Publishing
      • 4.4.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Product Registration & Clinical Trial Applications
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Other Services
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Regulatory Affairs Market: Category Estimates & Trend Analysis

  • 5.1. Category Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Regulatory Affairs Market by Category Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Drugs
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Innovator
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.2. Preclinical
      • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.3. Clinical
      • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.4. Pre-Maker Approval (PMA)
      • 5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Generics
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.2. Preclinical
      • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.3. Clinical
      • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.4. Pre-Maker Approval (PMA)
      • 5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Biologics
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Biotech
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.2. Preclinical
      • 5.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.3. Clinical
      • 5.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.4. Pre-Maker Approval (PMA)
      • 5.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. ATMP
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3.2. Preclinical
      • 5.4.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3.3. Clinical
      • 5.4.2.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3.4. Pre-Maker Approval (PMA)
      • 5.4.2.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Biosimilars
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.2. Preclinical
      • 5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.3. Clinical
      • 5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.4. Pre-Maker Approval (PMA)
      • 5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Medical Devices
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.2. Diagnostics
      • 5.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.2.2. Preclinical
      • 5.4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.2.3. Clinical
      • 5.4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.2.4. Pre-Maker Approval (PMA)
      • 5.4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.3. Therapeutics
      • 5.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.3.2. Preclinical
      • 5.4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.3.3. Clinical
      • 5.4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.4.3.4. Pre-Maker Approval (PMA)
      • 5.4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Regulatory Affairs Market: Indication Estimates & Trend Analysis

  • 6.1. Indication Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Regulatory Affairs Market by Indication Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oncology
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Neurology
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Cardiology
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Immunology
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Regulatory Affairs Market: Product Stage Estimates & Trend Analysis

  • 7.1. Product Stage Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Regulatory Affairs Market by Product Stage Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Preclinical
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Clinical studies
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. PMA
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Regulatory Affairs Market: Service Provider Estimates & Trend Analysis

  • 8.1. Service Provider Market Share, 2023 & 2030
  • 8.2. Segment Dashboard
  • 8.3. U.S. Regulatory Affairs Market by Service Provider Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. In-house
      • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Outsourced
      • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. U.S. Regulatory Affairs Market: Company Size Estimates & Trend Analysis

  • 9.1. Company Size Market Share, 2023 & 2030
  • 9.2. Segment Dashboard
  • 9.3. U.S. Regulatory Affairs Market by Company Size Outlook
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 9.4.1. Small
      • 9.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.2. Medium
      • 9.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.3. Large
      • 9.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. U.S. Regulatory Affairs Market: End-use Estimates & Trend Analysis

  • 10.1. End-use Market Share, 2023 & 2030
  • 10.2. Segment Dashboard
  • 10.3. U.S. Regulatory Affairs Market by End-use Outlook
  • 10.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 10.4.1. Medical Device Companies
      • 10.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.2. Pharmaceutical Companies
      • 10.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.3. Biotechnology Companies
      • 10.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. U.S. Regulatory Affairs Market: Region Estimates & Trend Analysis

  • 11.1. Regional Market Share, 2023 & 2030
  • 11.2. U.S. Regulatory Affairs Market by Region Outlook
  • 11.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 11.3.1. West
      • 11.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 11.3.2. Midwest
      • 11.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 11.3.3. Northeast
      • 11.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 11.3.4. Southwest
      • 11.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 11.3.5. Southeast
      • 11.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 12. Competitive Landscape

  • 12.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 12.2. Company/Competition Categorization
  • 12.3. Vendor Landscape
    • 12.3.1. List of key distributors and channel partners
    • 12.3.2. Key customers
    • 12.3.3. Key company market share analysis, 2023
  • 12.4. Company Profiles
    • 12.4.1. Accell Clinical Research, LLC
      • 12.4.1.1. Company overview
      • 12.4.1.2. Financial performance
      • 12.4.1.3. Product benchmarking
      • 12.4.1.4. Strategic initiatives
    • 12.4.2. Genpact
      • 12.4.2.1. Company overview
      • 12.4.2.2. Financial performance
      • 12.4.2.3. Product benchmarking
      • 12.4.2.4. Strategic initiatives
    • 12.4.3. CRITERIUM, INC.
      • 12.4.3.1. Company overview
      • 12.4.3.2. Financial performance
      • 12.4.3.3. Product benchmarking
      • 12.4.3.4. Strategic initiatives
    • 12.4.4. ICON plc
      • 12.4.4.1. Company overview
      • 12.4.4.2. Financial performance
      • 12.4.4.3. Product benchmarking
      • 12.4.4.4. Strategic initiatives
    • 12.4.5. Promedica International
      • 12.4.5.1. Company overview
      • 12.4.5.2. Financial performance
      • 12.4.5.3. Product benchmarking
      • 12.4.5.4. Strategic initiatives
    • 12.4.6. WuXi AppTec
      • 12.4.6.1. Company overview
      • 12.4.6.2. Financial performance
      • 12.4.6.3. Product benchmarking
      • 12.4.6.4. Strategic initiatives
    • 12.4.7. Medpace
      • 12.4.7.1. Company overview
      • 12.4.7.2. Financial performance
      • 12.4.7.3. Product benchmarking
      • 12.4.7.4. Strategic initiatives
    • 12.4.8. Charles River Laboratories
      • 12.4.8.1. Company overview
      • 12.4.8.2. Financial performance
      • 12.4.8.3. Product benchmarking
      • 12.4.8.4. Strategic initiatives
    • 12.4.9. Labcorp Drug Development
      • 12.4.9.1. Company overview
      • 12.4.9.2. Financial performance
      • 12.4.9.3. Product benchmarking
      • 12.4.9.4. Strategic initiatives
    • 12.4.10. Parexel International (MA) Corporation
      • 12.4.10.1. Company overview
      • 12.4.10.2. Financial performance
      • 12.4.10.3. Product benchmarking
      • 12.4.10.4. Strategic initiatives
    • 12.4.11. Freyr
      • 12.4.11.1. Company overview
      • 12.4.11.2. Financial performance
      • 12.4.11.3. Product benchmarking
      • 12.4.11.4. Strategic initiatives
    • 12.4.12. Pharmalex GmbH
      • 12.4.12.1. Company overview
      • 12.4.12.2. Financial performance
      • 12.4.12.3. Product benchmarking
      • 12.4.12.4. Strategic initiatives
    • 12.4.13. NDA Group AB
      • 12.4.13.1. Company overview
      • 12.4.13.2. Financial performance
      • 12.4.13.3. Product benchmarking
      • 12.4.13.4. Strategic initiatives
    • 12.4.14. Qvigilance
      • 12.4.14.1. Company overview
      • 12.4.14.2. Financial performance
      • 12.4.14.3. Product benchmarking
      • 12.4.14.4. Strategic initiatives
    • 12.4.15. BlueReg
      • 12.4.15.1. Company overview
      • 12.4.15.2. Financial performance
      • 12.4.15.3. Product benchmarking
      • 12.4.15.4. Strategic initiatives
    • 12.4.16. Cambridge Regulatory Services
      • 12.4.16.1. Company overview
      • 12.4.16.2. Financial performance
      • 12.4.16.3. Product benchmarking
      • 12.4.16.4. Strategic initiatives
    • 12.4.17. VCLS
      • 12.4.17.1. Company overview
      • 12.4.17.2. Financial performance
      • 12.4.17.3. Product benchmarking
      • 12.4.17.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-278-3

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. regulatory affairs market, by services, 2018 - 2030 (USD Million)
  • Table 3 U.S. regulatory affairs market, by writing & publishing, 2018 - 2030 (USD Million)
  • Table 4 U.S. regulatory affairs market, by category, 2018 - 2030 (USD Million)
  • Table 5 U.S. regulatory affairs market, by drugs, 2018 - 2030 (USD Million)
  • Table 6 U.S. regulatory affairs market, by innovator, 2018 - 2030 (USD Million)
  • Table 7 U.S. regulatory affairs market, by generics, 2018 - 2030 (USD Million)
  • Table 8 U.S. regulatory affairs market, by biologics, 2018 - 2030 (USD Million)
  • Table 9 U.S. regulatory affairs market, by biotech, 2018 - 2030 (USD Million)
  • Table 10 U.S. regulatory affairs market, by ATMP, 2018 - 2030 (USD Million)
  • Table 11 U.S. regulatory affairs market, by biosimilars, 2018 - 2030 (USD Million)
  • Table 12 U.S. regulatory affairs market, by medical devices, 2018 - 2030 (USD Million)
  • Table 13 U.S. regulatory affairs market, by diagnostics, 2018 - 2030 (USD Million)
  • Table 14 U.S. regulatory affairs market, by therapeutics, 2018 - 2030 (USD Million)
  • Table 15 U.S. regulatory affairs market, by indication, 2018 - 2030 (USD Million)
  • Table 16 U.S. regulatory affairs market, by product stage, 2018 - 2030 (USD Million)
  • Table 17 U.S. regulatory affairs market, by service provider, 2018 - 2030 (USD Million)
  • Table 18 U.S. regulatory affairs market, by company size, 2018 - 2030 (USD Million)
  • Table 19 U.S. regulatory affairs market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 U.S. regulatory affairs market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. regulatory affairs market: market outlook
  • Fig. 9 U.S. regulatory affairs competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. regulatory affairs market driver impact
  • Fig. 14 U.S. regulatory affairs market restraint impact
  • Fig. 15 U.S. regulatory affairs market: Services movement analysis
  • Fig. 16 U.S. regulatory affairs market: Services outlook and key takeaways
  • Fig. 17 Regulatory consulting market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Legal representation estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Regulatory writing & publishing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Writing estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Publishing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Product Registration & Clinical Trial Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others services estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. regulatory affairs market: Category movement Analysis
  • Fig. 25 U.S. regulatory affairs market: Category outlook and key takeaways
  • Fig. 26 Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Innovator market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Generics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 ATMP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Biosimilars market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Medical Devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. regulatory affairs market: indication movement analysis
  • Fig. 56 U.S. regulatory affairs market: indication outlook and key takeaways
  • Fig. 57 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 U.S. regulatory affairs market: product stage outlook and key takeaways
  • Fig. 63 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Clinical studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 PMA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. regulatory affairs market: service provider outlook and key takeaways
  • Fig. 67 In-house market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Outsourced market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 U.S. regulatory affairs market: company size outlook and key takeaways
  • Fig. 70 Small market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Medium market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Large market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 U.S. regulatory affairs market: end-use outlook and key takeaways
  • Fig. 74 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. regulatory affairs market: Regional movement analysis
  • Fig. 78 U.S. regulatory affairs market: Regional outlook and key takeaways
  • Fig. 79 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!